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Summary
Recent advances in the identification and characterisation of stem cell populations has led to substantial inter-
est in understanding the precise triggers that would operate to induce activation of quiescent stem cells.
Melanocyte stem cells (MSCs) reside in the bulge region of the hair follicles and are characterised by reduced
expression of the microphthalmia-associated transcription factor (Mitf) and its target genes implicated in
differentiation. Vitiligo is characterised by progressive destruction of differentiated melanocytes. However,
therapies using UV irradiation therapy can induce a degree of repigmentation, suggesting that MSCs may be
activated. As Mitf is implicated in control of proliferation, we have explored the possibility that inducing Mitf
expression via lipid-mediated activation of the p38 stress-signalling pathway may represent a re-pigmentation
strategy. Here we have isolated from placental extract a C18:0 sphingolipid able to induce Mitf and tyrosinase
expression via activation of the p38 stress-signalling pathway. Strikingly, in age-onset gray-haired C57BL ⁄6J
mice that exhibit decaying Mitf expression, topical application of placental sphingolipid leads to increased
Mitf in follicular melanocytes and fresh dense black hair growth. The results raise the possibility that lipid-
mediated activation of the p38 pathway may represent a novel approach to an effective vitiligo therapy.
Introduction
Cutaneous pigmentation plays an important role in
photoprotection from solar ultraviolet radiation (Kaidbey
et al., 1979; Kollias et al., 1991). In the hypopigmention
disorder, vitiligo (Westerhof and d’Ischia, 2007; Spritz,
2007), melanin-producing cells, melanocytes, histologi-
cally disappear. Understanding how to achieve the
recovery of melanin and functional melanocytes in viti-
ligo patients is a major goal. Current therapies, reviewed
in Falabella and Barona (2009) are only partially effective
and frequently involve the use of UV irradiation, a DNA-
Significance
Vitiligo is characterised by progressive destruction of melanocytes. Although treatment strategies involv-
ing UV irradiation can be partially effective, UV may also induce DNA damage. A more effective therapy
is urgently needed. Here we have shown that topical application of a lipid fraction can lead to an effective
reversal of age-associated hair graying in mice. The results suggest that lipid-mediated activation of p38
stress signalling may represent a potentially effective therapy for vitiligo.
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damaging agent. The non-availability of a satisfactory
adjuvant therapy to treat this disorder has led to the
search for new therapeutic agents capable of inducing
melanoblast and melanocyte survival, proliferation, dif-
ferentiation and melanogenesis. As some degree of
re-pigmentation is possible in many cases of vitiligo, it
is possible that while mature, differentiated melano-
cytes are lost, the non-pigmented melanocyte stem cell
(MSC) population may remain intact. Thus, strategies
designed to activate MSCs may be effective.
Recently we reported that a sphingolipid-rich placental
total lipid fraction (PTLF) derived from human placenta,
a rich reservoir of important biomolecules, contained
activities able to induce pigmentation (Mallick et al.,
2002, 2005). We subsequently showed that a nearly
purified placental sphingolipid (PSL) was active as a
melanin-inducing agent with mitogenic activity at low
and melanogenic activity at high concentrations (Saha
et al., 2006a). PSL was isolated from a vehicle-free pro-
totype hydroalcoholic human placental extract (Bhadra
et al., 1994, 1997, 1998; Pal et al., 1995), which
showed pigmentation in guinea pig and C57BL ⁄6J
mouse animal models (Pal et al., 1995, 2002). The origi-
nal extract was found to contain among others, lipid
constituents with at least four sphingolipids (Pal et al.,
1995) and screening led to identify PSL (Saha et al.,
2006a) as a highly melanogenic agent. PSL was purified
from this extract through a series of chromatography
steps and finally obtained as a single spot by prepara-
tive high-performance thin layer chromatography
(HPTLC). The HPTLC-purified PSL showed no resem-
blance with other standard sphingolipids spots in thin
layer chromatography (TLC) (Saha et al., 2006a). Among
the standard sphingolipids or sphingolipid metabolites,
that modulate pigmentation, only sphingosylphosphoryl-
choline (SPC) is melanogenic but soluble in water
(Higuchi et al., 2003). By contrast, while PSL is also
highly melanogenic, its solubility is organic solvent-
specific (Saha et al., 2006a).
The molecular mechanism underlying PTLF-induced
pigmentation was identified as being via activation of
the p38 stress-activated signalling cascade which, via
phosphorylation and activation of the cyclicAMP-
response element-binding protein (CREB) leads to induc-
tion of Mitf transcription and subsequent activation of
the tyrosinase gene and pigmentation (Mallick et al.,
2005; Singh et al., 2005; Saha et al., 2006a,b). However,
the kinases upstream and downstream of p38 required
for activation of Mitf were not previously identified.
Here, we further characterise the chemical structural
features of PSL, its capacity to activate specific compo-
nents of the p38 kinase pathway and importantly dem-
onstrate its effectiveness in stimulating pigmentation in
C57BL ⁄6J mice having age-onset hair graying. The
results suggest that the PSL-induced signalling pathway
may represent a safe and satisfactory therapeutic agent
for treating hypopigmentary disorder, such as, vitiligo.
Results
Characterisation of bioactive PSL
As reported earlier (Saha et al., 2006a), PSL was iso-
lated from a hydroalcoholic human placental extract by
sequential column chromatography using silicic-acid and
Sephadex LH 20 column and finally by scraping the sin-
gle spot from a preparative HPTLC plate after repeated
HPTLC to get a homogeneous spherical single spot
starting from the hydroalcoholic extract of human pla-
centa (Bhadra et al., 1994, 1997, 1998) (Figure 1A). The
purity of HPTLC-purified PSL was analyzed by high-per-
formance liquid chromatography (HPLC) (Figure 1B). A
comparative TLC analysis with melanocyte activity-mod-
ulating sphingolipid metabolites are also shown therein
indicating clearly that it differs distinctly from a known
melanocyte mitogenic SPC (Figure 1A). Again SPC is
soluble in water while PSL is not and requires organic
solvents for solubilisation. Thus, PSL is not a previously
known melanocyte-modulating sphingolipid metabolite.
A
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Figure 1. Thin layer chromatography (TLC) of sphingolipids and
high-performance thin layer chromatography of bioactive placental
sphingolipid (PSL). (A) TLC of sphingolipids was analyzed using
solvent system CHCL3 ⁄ MeOH ⁄ H2O (14:6:1 v ⁄ v ⁄ v) and detected by
spraying the plate with primuline and made visible and
photographed by illuminating under UV at 365 nm. Lane1: PTLF;
lane 2: PSL; lane 3: SPC; lane 4: Sphingosine; lane 5: S1P
(sphingosine-1-phosphate); lane 6: C2-Cer (C2-ceramide); lane 7:
C6-Cer (C6-ceramide); lane 8: GC (glucosylceramide); lane 9: LC
(lactosylceramide); lane 10: SSM (Stearoylsphingomyelin); lane 11:
PSM (palmitoylsphingomyelin). Arrow in (A) denotes the PSL spot.
(B) HPLC chromatogram of the HPTLC-purified PSL.
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Matrix-assisted laser desorption ⁄ ionisation time-of-
flight (MALDI-TOF) mass spectroscopy of the bioactive
PSL showed several characteristic peaks at 301,
379,760,782 and 799 (Figure 2A). The highest molecular
mass (M) of PSL generated is 759 [(M+H)+ = 760,
(M+Na)+ = 782, (M+K)+ = 799]. The 301 and 379 peaks
indicated the presence of sphingosine and sphingosine
phosphate in the PSL while the fatty acid analysis of
PSL indicated the presence of C18:0 (methyloliate) and
C16:0 (methylpalmitate) fatty acyl chains (Figure 2B).
Purified PSL induces dendrite outgrowth, tyrosinase
expression and melanogenesis in human
melanocytes
Although previously we reported that PSL induced mela-
nin synthesis in B16F10 mouse melanoma cells (Saha
et al., 2006a), we also wished to evaluate the effects of
this bioactive sphingolipid on cell morphology and mela-
nogenesis in human melanocytes. Distinct morphological
changes and dihydroxyphenylalanine (DOPA) staining of
melanocytes were observed 3–4 days after addition of
stimulants as evidenced by phase contrast microscopy
(Figure 3A). Most of the untreated control melanocytes
exhibited bipolar dendricity with basal pigmentation lev-
els (Figure 3A: a, b). Compared to the control cells, treat-
ment of melanocytes with 10 lg ⁄ml of PSL induced
higher number of elongated dendrites and much higher
DOPA staining reflecting increased melanin pigmenta-
tion (Figure 3A: c, d).
Tyrosinase is regulatory on the mammalian melano-
genesis and the effects of PSL on its expression at the
protein level in the cultured normal human melanocytes
was analysed by immunofluorescence. The results (Fig-
ure 3B), revealed higher levels of tyrosinase was
expressed in melanocytes after 72 h exposure to
10 lg ⁄ml PSL compared to the basal level in untreated
cells.
PSL activates the MKK3 ⁄6, p38, and MAPKAPK2 and
MSK1 to induce Mitf promoter activity and
subsequently tyrosinase gene expression
In our previous studies, involving sphingolipid-enriched
PTLF-mediated melanogenic signal transduction in
B16F10 melanoma, we reported that p38 MAPK ⁄CREB-
mediated activation of Mitf gene expression leads to
enhanced tyrosinase gene expression (Singh et al.,
Figure 2. (A) Matrix-assisted laser
desorption ⁄ ionisation time-of-flight mass
spectrum of bioactive placental
sphingolipid (PSL). (B) Fatty acid profile of
PSL. Fatty acid methyl esters were
obtained by methanolysis procedure as
described in the ‘Materials and methods’.
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2005; Saha et al., 2006b). Here we determined the role
of p38 MAPK-upstream kinases (MKKs) in this signalling
cascade and the relevant fate of p38 MAPK substrate,
CREB kinases. As, the cell cycle of primary melanocytes
is very long (8–12 days) and normal healthy human skin
was not easily available, the signalling studies were per-
formed in the B16F10 mouse melanoma cell system.
As shown in Figure 4A, modest MKK3 (lower band) and
MKK6 (upper band) activation was detected under rest-
ing conditions and a significant increase in MKK3 phos-
phorylation (2.9-fold) (P < 0.01) was first observed
within 30 min of exposure to PSL and peaked (4.1-fold)
(P < 0.001) at about 60 min followed by a gradual
decline to the basal level by 12 h. MKK6 phosphoryla-
tion was low in comparison to MKK3 phosphorylation as
a very modest increase (1.8-fold) (P < 0.01) of MKK6
was detected after 1 h of PSL stimulation. Thus MKK3
and MKK6 activation correlates well with time-depen-
dent phosphorylation of p38 MAPK. These data
suggested that MKK3 is more preferably activated
than MKK6 in B16F10 after bioactive sphingolipids
stimulation.
To determine the relative contribution of MKK3 and
MKK6 to PSL-stimulated p38 MAPK activation, we ana-
lyzed the phosphorylation levels of p38 MAPK and p38
MAPK kinase activity in B16F10 cells transfected with
dominant negative (DN) MKK3 plasmid, pRSV-Flag-
MKK3 (Ala) and DN MKK6 plasmid, pCDNA3-Flag-MKK6
(K82A) (Raingeaud et al., 1996) (a generous gift from
Dr Roger Davis) separately and in combination. As
shown in Figure 4B, cells transfected with DN plasmids
express greater levels of immunoreactive MKK3 and
MKK6 proteins compared with empty vector pcDNA3.1-
transfected cells. The expression of phospho-p38 MAPK
and correspondingly p38 MAP kinase activity were
induced in PSL-induced empty vector transfected
B16F10 cells compared with unstimulated but identically
transfected cells. The DN MKK3 and DN MKK6 clones
alone modestly decreased the levels of phospho p38
and p38 MAP kinase activity. However, cotransfection
with both DN constructs synergistically reduced phos-
pho-p38 MAPK compared with unstimulated empty vec-
tor-transfected B16F10 cells. These data suggested that
both MKK3 and MKK6 nearly equally contribute to the
PSL-stimulated p38 phosphorylation and kinase activity.
However, for full activation of p38 by PSL treatment the
kinase activities of both of the MKKs are essential.
We next determined the CREB-kinases responsible
for PSL-induction of CREB phosphorylation in serine
133. We observed that phosphorylation of MAPKAPK2,
an immediate downstream target of p38 MAPK (Stokoe
et al., 1993) was evident after 30 min (2.4-fold)
(P < 0.01) and followed a time dependent manner with
maximum activation after 1 h (3.9-fold) (P < 0.001) and
then gradually declined to the basal level by 12 h (Fig-
ure 5A, B, upper panel). The phosphorylation pattern of
MAPKAPK2 was correlated well with an increase in its
kinase activity (Figure 5A, B, middle panel). MAPKAPK2
was immunoprecipitated from control and PSL-treated
cells and the immune complexes were assayed for
phosphorylation of recombinant Hsp27 substrate, in an
in vitro kinase assay with maximum activation observed
at 1 h (5.57-fold) (P < 0.01) time point. The effect of
PSL was also examined on another CREB kinase, MSK1
(Deak et al., 1998), which was activated only minimally
(1.6-fold, after 1 h) (P < 0.01) compared to the control
(Figure 5A, B, lower panel). These observations sug-
gested that of the CREB kinases, downstream of p38
MAPK, PSL more preferentially and effectively stimu-
lates MAPKAPK2 phosphorylation.
We also found that PSL induced a 5.3-fold (P < 0.001)
and 4.8-fold (P < 0.001) (Figure 5C) increase in Mitf and
tyrosinase promoter activity, respectively, compared
with unstimulated controls and this PSL-responsiveness
of Mitf promoter and subsequently tyrosinase promoter
A
B
Figure 3. (A) Dendritogenesis and melanogenesis as shown by
DOPA staining in normal human primary melanocytes after 4 days
in the presence of PSL using the medium as described in the
‘Materials and methods’. Untreated cells (a, b), 10.0 lg ⁄ ml of PSL
(c, d). All cells were photographed under equal magnification by
inverted phase contrast microscope. Bar represents 30 lm.
(B) Immunoflurorescence labeling of human melanocytes
stimulated with or without 10 lg ⁄ ml PSL for 72 h to identify
tyrosinase proteins as described in the ‘Materials and methods’.
The tyrosinase proteins (green) (left panel) and nuclei of the cells
by DAPI staining (blue) (right panel) were visualised by
immunofluorescence in an inverted fluorescence microscope. All
photographs are under equal magnification and bar represents
20 lm.
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Figure 4. (A) A time course of phosphorylation of MKK3 ⁄ 6 (upper panel) and p38 MAPK (lower panel) in B16F10 cells in response to
10 lg ⁄ ml PSL for 0–12 h as indicated. MKK3 ⁄ 6 phosphorylation and p38 phosphorylation were analyzed by Western blot using anti-phospho
MKK3 ⁄ 6 antibody (Ser 189 ⁄ 207)and anti-phospho p38 MAPK antibody (Thr 180 ⁄ Tyr 182) respectively and MKK3 or MKK6 or p38 antibodies
as loading control. Densitometric scanning of the band intensities of phospho-MKK3 ⁄ 6 (upper panel) and phospho p38 MAPK (lower panel)
obtained from three separate experiments. The cumulative (control value taken as one fold in each case) data are presented as mean ± SE.
*P < 0.01, **P < 0.001. (B) Effect of DN MKK3 and DN MKK6 on PSL-induced p38 MAPK phosphorylation and p38 MAP kinase activity.
B16F10 cells transfected with either empty vector or DN clones as indicated. At 24 h after transfection the cells were stimulated with PSL for
1 h. Total proteins were extracted and evaluated by Western blot analysis using anti phospho-p38 MAPK, anti phospho-MKK3 ⁄ 6, anti MKK6
and anti MKK3 antibodies and b-actin antibody as loading control. p38 MAPK activity was determined by in vitro kinase assays using specific
immunoprecipitation with anti-phospho-specific p38 MAP Kinase antibody followed by an in vitro kinase assay of its substrate, ATF-2.
Densitometric scanning of the band intensities of phospho-p38 MAPK and phosphorylated ATF-2 obtained from three separate experiments.
The cumulative (control value taken as one fold in each case) data are presented as mean ± SE. *P < 0.02, **P < 0.01. 3DN = DN MKK3, 6
DN = DN MKK6, 3 ⁄ 6 DN = cotransfection with DN MKK3 and DN MKK6.
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Figure 5. (A) A time course of phosphorylation of MAPKAPK2 (upper panel), MAPKAPK2 kinase activity, CREB phosphorylation (middle panel)
and MSK1 phosphorylation (lower panel) in B16F10 cells in response to 10 lg ⁄ ml of PSL for 0–12 h as indicated. MAPKAPK2, CREB and
MSK1 phosphorylation were analyzed by Western blot using antibody specific for Thr 222-phosphorylation of MAPKAPK2, antibody specific
for Ser 133-phosphorylation of CREB and antibody specific for Ser 376-phosphorylation of MSK1; and MAPKAPK2, CREB and MSK1
antibodies as loading control. MAPKAPK2 activity was measured by a specific immunoprecipitation with anti-phospho-specific MAPKAPK2
antibody followed by an in vitro kinase assay of its substrate, hsp-27 as described in the ‘Materials and methods’. (B) Densitometric scanning
of the band intensities of phospho-MAPKAPK2 (upper panel), phosphorylated hsp-27 and phospho-CREB (middle panel) and phospho-MSK1
(lower panel) obtained from three separate experiments. The cumulative (control value taken as one fold in each case) data are presented as
mean ± SE. *P < 0.01, **P < 0.001. (C) Effect of PSL on Mitf and tyrosinase promoter activity. Mitf and tyrosinase promoter activity was
detected in B16F10 cells transfected with pMI (containing Mitf promoter upstream of the luciferase coding sequence) or pMT (containing a
2.2-kb pair fragment of the tyrosinase promoter upstream of the luciferase coding sequence as a reporter gene) along with pCMVbGal. Then
cells were treated for 6 h or 12 h for pMI or pMT respectively with PSL. Luciferase activity was normalised by pCMVb-galactosidase activity
and the results were expressed as fold stimulation of luciferase activity from unstimulated control. The cumulative (control value taken as
one-fold in each case) data are presented as mean ± SE. *P < 0.02.
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was higher when compared with PTLF (100 lg ⁄ml) as
reported before (Saha et al., 2006b). These results
agree with our earlier observations of higher protein and
mRNA expression of tyrosinase in PSL-treated cells
than that in PTLF-treated B16F10 cells (Saha et al.,
2006a). Thus, it is conceivable that the purified bioactive
PSL transduces melanogenic signals within cells more
effectively when applied solely in purified form than in a
mixture with other lipids in PTLF.
Induction of skin and hair pigmentation by PSL in
age onset gray-haired C57BL ⁄6J mice
The results presented so far indicate that in cultured
cells PSL induces pigmentation via p38 signalling-medi-
ated activation of Mitf and Tyrosinase expression. To
determine the effects of PSL on pigmentation in vivo
we used the C57BL ⁄6J mouse model that exhibits age-
related hair graying. After removal of gray hair of
C57BL ⁄6J mice by clipping, PSL was applied topically to
the skin. Vehicle only-treated skin from the same mouse
was used as a control. In contrast to vehicle (60% aque-
ous alcohol-) treated region which did not show any
marked change in skin color from the initial pinkish
appearance (Figure 6A: a), within 12 days of PSL
application the skin in the PSL-treated region took on a
bluish appearance (Figure 6A: b), and as the experimen-
tation progressed the color darkened gradually. Within
25 days black hair started appearing in the PSL treated
region (Figure 6A: c) similar to that found in young ani-
mals reverting telogenic phase of hair growth cycle to
anagen whereas the vehicle-treated region exhibited
nearly unchanged gray hairs (data not shown).
Mouse skin specimens from both the vehicle and
PSL-treated sites were examined histologically under
both the longitudinal (Figure 6B: a, b) and cross-
sectional (Figure 6B: c, d) views after Masson–Fontana
staining to compare skin organisation, melanisation and
the hair follicle formation. Longitudinal view of PSL-
treated skin specimen (Figure 6B: b) shows new hair
follicles rooted beyond the dermis in the bulbs and
embedded into the adipocyte layer unlike the vehicle-
treated ones having hair bulbs within dermis (Figure 6B:
a). In the cross-sectional view of the experimental speci-
men (Figure 6B: d), a large number of hair follicles along
with corresponding melanising centers was observed
compared to a few in vehicle-treated skin (Figure 6B: c).
a
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Figure 6. (A) Effect of placental
sphingolipid (PSL) application on skin and
hair pigmentation in C57BL ⁄ 6J mice at
the age-induced telogenic stage of hair
growth, marked by pinkish skin and
graying of hair (a) and (b). Vehicle and
PSL-applied regions on the right and left
sides respectively of the same mouse.
Arrow in (b) denotes the PSL-treated
region with the recurrence of the anagenic
stage, as manifested by appearance of
bluish skin. The arrow in (a) denotes
control (vehicle)-treated zone with no such
growth cycle reversal. (c) PSL-applied
regions (arrow) on the left side of the
mouse shows distinct indications of
growth cycle reversal to the anagenic
stage, as shown by the growth of deep
black shiny hair. (B) Longitudinal (a, b) and
cross-sectional (c, d) views of the skin
specimens stained with Masson and
Fontana stain; (a) Vehicle-treated mouse
skin where the hair follicles are short, thin,
few in number (arrow), and within the
dermal layer, which is dense or
hypotrophic as in the cross-sectional
sample. (b) PSL-treated mouse skin where
a hypertrophic structure and an ample
number of new hair follicles can be seen
(arrow) in the adipocyte layer
(magnification, ·200). (c) Vehicle-treated
mouse skin with a few melanising centers
(arrow) in the dermal layer which is dense
or hypotrophic. (d) PSL-treated mouse skin
with a large number of melanising centers
(arrow), (magnification, ·400).
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Effect of PSL on Mitf expression of Hair follicle
melanocytes-subpopulations in an age onset gray
haired C57BL ⁄6J mouse
In C57BL ⁄6J black mice, melanocytes progressively dis-
appear from the epidermis shortly after birth and are
present only in the hair follicle (Yoshida et al., 1996). In
the hair follicle, MSCs are maintained in the niche at the
bulge region of the hair follicle, whereas, fully differenti-
ated melanocytes reside in the hair bulb adjacent to the
upper part of the dermal papilla (Nishimura et al., 2002;
Fuchs et al., 2001). Mitf is expressed in differentiating
melanoblasts and fully differentiated melanogenically
active melanocytes but not in non-differentiated melano-
cyte stem cells (Osawa et al., 2005; Nishimura et al.,
2005). Thus, Mitf may be considered as a sensitive and
specific melanocyte marker for identifying the non-stem
cell melanocyte populations (King et al., 1999). We used
Mitf immunostaining to visualise the expression of Mitf
in the hair follicle melanocytes in both vehicle and PSL-
treated skin. In the hair follicles of vehicle-treated skin
(Figure 7A) there were few Mitf+ cells in both the hair
bulb and bulge regions representing differentiated mela-
nocytes and undifferentiated melanoblasts, respectively.
This is consistent with the characteristics of physiologi-
cal hair graying with gradual loss of both undifferenti-
ated MSCs and differentiated melanocytes from hair
follicle niche and hair matrix, respectively, with aging
(Nishimura et al., 2005). By contrast, numerous strongly
Mitf-expressing melanocytes (higher green fluores-
cence) with dendritic appearance were observed in hair
bulbs adjacent to the dermal papilla of PSL-induced ana-
genic hair follicles (Figure 7B, C and D). These were
assumed to be differentiated melanocytes. A large num-
ber of Mitf+ cells were also located at the outer root
sheath around the bulge region of PSL-induced anagenic
hair follicle (Figure 7B, C). These are comparatively small
and round in shape and most likely represented undiffer-
entiated melanoblasts or a transit amplifying population
derived from MSCs. The level of Mitf expression is
therefore markedly upregulated in both the melanocytes
and melanoblast subpopulations of the hair bulb and
outer root sheath of PSL-treated skin specimen com-
pared with vehicle-treated skin specimen where the
intensity of staining for Mitf was significantly low.
Discussion
The results presented here provide evidence that a
novel, alcohol-soluble C18:0 sphingolipid (PSL) derived
from placental extract is able to stimulate melanogene-
sis and increase dendricity in melanocytes. The
molecular mechanism underlying the PSL-mediated
pigmentation was shown to be mediated via the p38
stress signalling pathway in which PSL activates both
MKK6 and MKK3 which in turn leads to activation of
p38 kinase and its downstream effector MAPKAPK2,
A B
C D
Figure 7. Immunohistochemical staining
for Mitf in vehicle (control) and PSL-
applied skin of C57BL ⁄ 6J mouse showing
distribution of Mitf+ cells (green
fluorescence) in anagenic hair follicles. (A)
Distribution of Mitf+ melanocytes (dashed
arrow) in hair bulb (Bb) and Mitf+
melanoblasts (solid arrow) on outer
rootsheath in the hair follicle of vehicle-
treated skin. (B) and (C) A large number of
Mitf+ melanocytes (dashed arrow) in the
hair matrix around the dermal papilla and
Mitf+ melanoblasts (solid arrow) on the
outer root sheath in the hair bulge (Bg) of
PSL-treated skin. Melanocytes are
identified with dendritic morphology;
melanoblasts are comparatively small and
rounded in shape. (magnification, ·200;
scale bar, 60 lm). (D) Magnified view of
hair follicle of PSL-treated skin.
Melanocytes (dashed arrow) are located in
the hair matrix above the dermal papilla,
(magnification, ·400; scale bar, 60 lm).
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and to a lesser extent MSK1. The ability of activated
MAPKAPK2 to phosphorylate and activate the transcrip-
tion factor CREB leads to increased expression from the
Mitf promoter and consequent activation of the Mitf tar-
get gene Tyrosinase. Our findings agree with earlier
reports where CREB phosphorylation on serine 133
occurred in a p38 MAPK ⁄MAPKAPK2-dependent man-
ner in SK-N-MC cells (Tan et al., 1996), PC12 cells
(Rouse et al., 1994) or CH31 B cell lymphoma (Swart
et al., 2000) in response to fibroblast growth factor
(FGF) and arsenite, nerve growth factor (NGF) or B cell
Ag receptor (BCR) ligation, respectively. Thus, PSL has
emerged as a highly potent pigment inducer and major
active principle of PTLF through its ability to enhance
Mitf expression and subsequently upregulation of tyrosi-
nase gene substantiating Mitf as a master transcription
regulator of melanocyte activity.
Vitiligo is characterised by progressive destruction of
differentiated melanocytes. However, the repigmentation
that can be achieved, for example by UV therapy, sug-
gests that non-pigmented Mitf-negative MSCs are likely
to remain intact. Indeed, hair follicles in vitiliginous
regions are the prime reservoir of melanocyte stem cells
(Fitzpatrick et al., 1983), which are, in turn, the primary
source of pigment recovery. Age-induced prolonged
telogen phase of hair growth cycle with the histological
disappearance of follicular melanocytes in C57BL ⁄6J
black mice (Slominski and Paus, 1993) displaying gray hair
is related to the depigmentation in vitiligo. Because the
life and activity of a melanocyte (proliferation and differen-
tiation) is tightly coupled with the hair growth cycle,
regrowth of the pigmented hair and appearance of
pigment in the skin, could be proposed synonymous with
the induced growth and melanogenesis of melanocytes,
concurring with repigmentation achieved in successful
vitiligo therapy (Medrano and Nordlund, 1990; Slominski
and Paus, 1993; Pal et al., 2002). If a prolonged telogen
phase of hair growth can be converted to the anagen
phase (visualized by a change in skin color with the
growth of black hair) using an agent, then it is expected
to be capable of inducing repigmentation in vitiligo lesions
(Ortonne and Prota, 1993; Pal et al., 2002). In this
respect, the ability of PSL to induce the appearance of
bluish skin and the growth of fresh black hair in PSL-trea-
ted mouse skin was striking, and indicated a quick
resumption of anagenic phase from prolonged telogenic
phase of hair growth cycle. Intriguingly, histological exam-
ination of PSL-treated skin revealed an enhancement in
the number of melanin-forming centres and an increased
number of new hair follicles similar to those found by
Cui et al. (1991) and Pal et al. (2002). The activity of the
purified PSL reported here is most likely related to the
effects of a complex mixture of peptides, amino acids
and different classes of lipid in a placental extract on skin
darkening in a guinea pig model (Pal et al., 1995) and hair
pigmentation coupled with hair growth in C57BL ⁄6J mice
(Pal et al., 2002).
Hair graying in both mouse and humans is caused by
lack of maintenance of MSCs in the niche of hair follicle
which results in loss of melanogenically active progeny
(melanocytes) in the hair matrix with aging (Nishimura
et al., 2005). Acceleration of this process by mutation of
the Mitf gene (Mitfvit) implicates Mitf in the self-renewal
and maintenance of MSCs (Nishimura et al., 2005). The
dependence of melanocyte development on Mitf
expression is obvious and the loss of viable melano-
blasts or melanocytes arises due to Mitf mutations
(Hodgkinson et al., 1993; Hughes et al., 1993). Mitf reg-
ulates melanocyte development, proliferation, survival
as well as differentiation (Tachibana, 2000; McGill et al.,
2002; Vance and Goding, 2004). In particular, it has
been demonstrated that depletion of Mitf in melanoma
cells leads to a G1-arrested stem-cell like phenotype
(Carreira et al., 2006). It seems likely, therefore, that
up-regulation of Mitf may represent a strategy for stimu-
lating reserve MSCs to divide. In normal stem cells,
activation of Mitf expression is likely to be controlled by
Wnt signalling via b-catenin to the Mitf promoter (Take-
da et al., 2000), as Wnt controls the generation of new
hair folicles (Silva-Vargas et al., 2005). In the case of the
repigmentation in the gray haired C57BL ⁄6J achieved
here, activation of Mitf expression most likely potenti-
ates MSC proliferation, migration to hair matrix and
subsequently differentiation into mature and melanogen-
ically active melanocytes in the hair bulb as a result
of PSL-mediated activation of p38, MAPKAPK2 and
CREB.
The appearance of pigmented skin after PSL treat-
ment in C57BL ⁄6J mouse is also significant. In mice,
melanocytes are generally confined to the hair follicles
in the epidermis (Yoshida et al., 1996). Nishimura et al.
(2002), demonstrated the epidermal repigmentation pro-
cess using Dct-lacZ ⁄+transgenic mice and showed that
bulge stem cells are the source of melanocytes in the
epidermis. Significantly, Mitf also regulates dendrite for-
mation and melanoblast migration (Carreira et al., 2006;
reviewed in Vance and Goding, 2004). Therefore, the
appearance of blue skin and subsequently growth of
anagenic black hairs after PSL application may be
explained by the enhancement of Mitf expression in the
bulge stem cells which then proliferate and migrate to
the epidermis and the hair bulb, undergo reactivation at
the next early anagen and differentiate to produce mela-
nin pigments. The phenomenon of differentiation of the
hair follicle premelanocytes into active forms and their
subsequent migration to the epidermis are the key
events for repigmentation in vitiligo lesions. The poten-
tial ability of the PSL to promote MSC division is of
crucial importance in view of any potential therapy for
vitiligo. Indeed, the pigment induction process in
C57BL ⁄6J mouse after PSL induction is reminiscent of
the pigment recovery process of human vitiligo, charac-
terised by loss of melanocytes. Based upon our results,
the following model (Figure 8) for the PSL-induced
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signalling pathways leading to melanogenesis is pro-
posed. Thus, the detail signalling pathway induced by
PSL provided the scientific basis to offer a safe and sat-
isfactory therapeutic use of PSL for pigment recovery in
depigmented skin diseases, such as, vitiligo.
Finally, while we have focused our attention here on
a use for PSL in vitiligo, we are also aware that the gen-
eration of sphingolipids and activation of Mitf via the
p38 signalling pathway may be an important event in
the UV-mediated tanning response. Further work will be
necessary to detemine the importance of lipid interme-
diates in UV stimulation of melanocytes.
Materials and methods
Materials
Diethyl ether, n-octanol, ethanol, HPLC grade methanol and water
were purchased from E Merck India Ltd, Mumbai, India. Isopropa-
nol, n-hexane, petroleum ether, chloroform, acetone from Spectro-
chem Pvt. Ltd., Mumbai, India; Silicic acid from SRL, Sisco
Research laboratory, Pvt. Ltd., Mumbai, India; Primulin and iodine
crystal from Sigma Chemical Co., St., Louis, MO, USA; TLC and
HPTLC plate from E. Merck, Germany. Dulbecco’s Modified Eagle
Medium (DMEM), fetal bovine serum (FBS), penicillin, streptomycin
and neomycin antibiotic, OPTI-MEM reduced serum medium and
other medium supplements were obtained from Gibco BRL (Grand
Island, NY, USA). Horseradish peroxidase-conjugated secondary
antibodies were from Sigma Chemical Co., St Louis, MO, USA.
MAPKAP Kinase2 Immunoprecipitation assay Kit (non-radioactive,
no. 17–297) was purchased from, Upstate, Lake Placid, NY. p38
MAP Kinase (Nonradioactive) Assay Kit (no. 9820), Chemilumines-
cent Horseradish peroxidase Western blot detection system (Lumi-
GLO Reagent and peroxide no. 7003) and primary antibodies
phospho-p38 MAP Kinase (Thr180 ⁄ Tyr182, no. 9211), p38 MAP
Kinase (no. 9212), phospho-CREB (Ser 133, no. 9191), CREB (no.
9192), phospho-MAPKAPK2 (Thr222) (no. 3044), MAPKAPK2 (no.
3042), phospho-MSK1 (Ser 376) (no. 9591), phospho-MKK3 ⁄ MKK6
(Ser189 ⁄ 207) (no. 9231), MKK3 (no. 9232), MKK6 (no. 9264) were
purchased from Cell Signaling Technology, Inc. Beverly, MA, USA.
Another primary antibodies MSK1 (no. sc-9392) and Actin (no.
sc-7210) were purchased from Santa Cruz Biotechnology, Inc. Santa
Cruz, CA, USA, Luciferase Assay System and b-Galactosidase
Enzyme Assay System were from Promega, Madison, WI, USA.
Cell culture
Normal human melanocytes (NHMC), derived from the surgical skin
specimen (provided by Prof. P. K. Dutta of Calcutta Medical Col-
lege), were cultured in an in vitro system according to the modified
method of Eisinger and Marko, 1982, and standardised in our labo-
ratory. Briefly, after removal of the subcutaneous fat, small pieces
of the skin specimen were prepared to treat with 0.25% trypsin,
0.05% EDTA, PSN in phosphate-buffered saline (PBS) overnight at
4C. The epidermis was separated from the dermis by the means
of forceps and the tissues were transferred to a centrifuge tube
containing trypsin solution and vortexed. The resulting cell suspen-
sion was centrifuged at 500 · g for 10 min to pellet down the cells.
The cells were resuspended in MCDB153 growth medium supple-
mented with 50 ng ⁄ ml of 12-O-tetradeconoyl phorbol 13-acetate,
0.1 mM isobutylmethyl xanthine, 6 ng ⁄ ml of bFGF, 5 lg ⁄ ml of ins-
lin, 1 lg ⁄ ml of transferrin, 0.18 lg ⁄ ml of hydrocortisone, 5% FBS
and PSN and plated onto 25 cm2 culture flasks and maintained in a
humidified incubator with 5% CO2 at 37C. Twenty-four hours later
medium was replaced and thereafter changed regularly every
2 days with fresh medium. When almost 70% confluency was
reached cells were passaged and used for the experiment. In
experiments to evaluate the effect of PSL on melanocytes, the
cells were seeded in 24 well plates at a density of 1 · 104 cells per
well. The medium used in the experiment was prepared without
supplementation or addition of the growth factors, TPA, BPE, IBMX
and bFGF.
B16F10, a mouse melanoma procured from National Centre for
Cell Science, Pune, India was cultured and maintained as before
(Mallick et al., 2002). Then 1 · 106 cells ⁄ well were plated and cul-
tured in DMEM for 24 h and the spent medium was removed with
continued culturing in DMEM with 2% heat-inactivated FBS and
1% PSN antibiotic, with or without supplementation of the
10 lg ⁄ ml of PSL.
Preparation of the PTLF and PSL in brief
Placental total lipid fraction was prepared from a vehicle-free proto-
type human-placental extract (Bhadra et al., 1998; Pal et al., 1995)
following the solvent partitioning technique (Siddiqui et al., 1998;
patent) as reported previously (Mallick et al., 2002, 2005) based on
a published method (Osborne, 1986). To make PSL, briefly, the
residual sticky mass obtained from the placental extract by flash
evaporation, was dissolved in N-octanol and loaded in silicic-acid
column and stepwise sequentially eluted by chloroform and metha-
nol gradient with increasing methanol concentration. The active
fraction was further resolved by chromatography using, sephadex-
LH20 column, and finally by preparative HPTLC. HPTLC resolved
single band was scraped off and repeatedly resolved and finally run
on a TLC plate with the solvent system chloroform–methanol–
water (14:6:1 v/v/v). A fine single spot of the lipid was lighted up in
Figure 8. Proposed model for stress-signalling pathways induced
by purified bioactive placental sphingolipid (PSL) leading to
melanogenesis.
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iodine, premulin and benzidine spray. PSL was found with high pig-
menting activity in B16F10 melanoma cells in vitro.
High-performance liquid chromatography analysis
High-performance liquid chromatography analysis of this purified
sphingolipid was performed to verify its purity. It was solubilised in
chloroform: methanol (2:1 v ⁄ v). Samples (10 ng) were run on the
column in a solvent system of linear gradient of isopropanol–hex-
ane–water (55:40:5–55:38:7 v/v/v) at a flow rate of 0.5 ml ⁄ min for
100 min and the fraction was detected at 210 nm with Photo diode
array detector. [HPLC Model used: LC-10AT, Shimadzu Corporation,
Japan]. The column used was Iatrobead 6RSP 8010, 4.6 Id X
250 mm, Iatron laboratories, Inc.
MALDI-TOF analysis of PSL
Matrix-assisted laser desorption ⁄ ionisation time-of-flight is useful
for structural investigation of lipids. The sample is dispersed in a
large excess of matrix material, which will strongly absorb the inci-
dent light. A high-voltage tube accelerates the ions formed where
they separate according to mass that is detected and recorded by
a high-speed recording device. MALDI-TOF analysis was done on
the placental purified sphingolipid (PSL) compound using Kratos PC
Kompact instrument and Kratos standard software for data han-
dling. The sample (1.0 mg) was dissolved in 100 ll of HPLC grade
chloroform. The sample 0.2 ll (2 lg) was then mixed with 1 ll of
the original matrix solution and spotted. The sample was charged
with nitrogen laser with defined wavelength of 337 nm, accelera-
tion voltage was to 20 kV. The ions were registered in a delayed
reflector mode with 150 s delay time.
Fatty-acid analysis of PSL
The fatty acids in PSL were qualitatively and quantitatively analyzed
by the method of Wollenweber et al., 1984. Briefly, 1 mg PSL was
treated with anhydrous 2 N methanolic HCl and heated at 85C for
16 h. The hydrolysate was concentrated using a N2 stream and an
equal volume of halfsaturated NaCl was added. The resulting
methyl esters of fatty acids were extracted with distilled chloro-
form and finally subjected to GLC and GLC-MS. Fatty acids were
determined as methyl ester derivatives by GLC comparing with
those of authentic standards and also by the analysis of electron
impact (EI) mass spectrometry.
Preparation of PSL for cell culture
As sphingolipids ⁄ ceramides are not soluble in aqueous medium
and are usually emulsified with a protein (like a bovine serum
albumin) to study their biological response (Zhang et al., 1990),
PSL was first dissolved in chloroform ⁄ methanol (2:1 v ⁄ v) to take
appropriate amounts in sterile experimental vials. After complete
removal of the solvent, medium (DMEM containing 2% heat-
inactivated FBS) was added, and then subjected to ultrasonication
for uniform dispersion suitable for sphingolipid uptake by cells in
culture. These were then used to study the effect of PSL by
adding to the culture removing the spent medium and replaced
by fresh medium. The viability of these cells was determined by
the MTT [3-(4, 5-dimethyl-thiazol-2-yl)-2, 5-diphenyltetrazolium
bromide] assay and trypan blue dye exclusion method (Mallick
et al., 2002).
DOPA staining
Melanocyte cell-specific DOPA staining was performed on mela-
nocytes according to the standard procedure of cell staining (Gil-
her et al., 1995). As stated earlier, human melanocytes cultured
and maintained in MCDB-153 medium was trypsinised and
seeded identically as for studying cellular morphology with a den-
sity of 1 · 103 cells ⁄ well of six-well TC-plates. After stipulated
time of incubation with the desired stimulants, the media were
aspirated off. The cells were fixed in 0.2 M cacodylate buffer con-
taining 1% formalin for 2 h at 4C. Following fixing in formalin
containing buffer, the buffer was aspirated off and cells were
washed to remove any formalin. The cells were finally incubated
in 0.2 M cacodylate buffer, pH 7.2, containing 1% L-DOPA for
3–4 h depending upon the intensity of the staining required. The
DOPA-stained cells were finally photographed.
Immunofluorescence staining
Immunofluorescence staining was carried out as described by Price
et al., 1998. Human melanocytes were grown for 24 h on glass
cover slips (2 · 104 cells ⁄ well) in a six-well plate and treated for
stipulated time with or without 10 lg ⁄ ml of PSL. Cells were then
rinsed briefly in 1· PBS fixed at room temperature for 20 min with
3% paraformaldehyde and permeabilised with pre-cold 100% meth-
anol at )20C for 5 min followed by blocking with 10% BSA in
PBS for 30 min at room temperature. Cells were then incubated
with primary antibody, anti-Tyrosinase (H-109) (1:100 dilution)
(Santa Cruz Biotechnology, Inc.) for 2 h at room temperature. After
washing with PBS three times, the cells were then incubated with
secondary antibody, fluorescein-conjugated goat anti-rabbit antibody
(1:50 dilution) (no. Sc-2012) (Santa Cruz Biotechnology, Inc.) for 1 h
at 4C. Then cells were washed in PBS and for DAPI staining, cells
were simultaneously fixed and permeabilised using 2% paraformal-
dehyde and stained with 1 lg ⁄ ml of DAPI for 10 min at room tem-
perature. The cells were viewed and photographed using inverted
fluorescence microscope (Model: OLYMPUS 1 · 70; Olympus
Optical Co. Ltd., Shibuya-ku, Tokyo, Japan).
Western blot analysis
Western blot analysis was performed to determine protein expres-
sion levels as previously described (Saha et al., 2006a,b). Briefly,
25 lg of total protein from each cell extract was electrophoresed in
reducing SDS–(10%) PAGE and blotted on Polyvinylidene Fluoride
(PVDF) membranes (Immobilon-P, Millipore Corporation, Bedford,
MA, USA) using a Transblot system (Transblot SD: Semidry transfer
cell; Bio-Rad Laboratories, Inc., Hercules, CA, USA). The mem-
branes were then probed with primary antibodies overnight at 4C
and then incubated with horseradish peroxidase conjugated second-
ary antibody and signals were visualised with enhanced chemilumi-
nescence (Cell Signaling Technology, Inc.). Loading control was
assessed using antibodies to p38 MAP Kinase, CREB, MKK3,
MKK6, MAPKAP kinase-2, and b-Actin. Membranes were processed
for densitometric analysis using an imaging densitometer (Model:
Image Scanner; Amersham Pharmacia Biotech, Buckinghamsire,
UK) and a Software (Image Master Total lab version 1.11, from
Phoretix, Newcastle upon Tyne, UK).
p38 MAPK assay
The activity of p38 MAP Kinase was analysed using a commercially
available kit (p38 MAP Kinase assay Kit; Cell Signaling Technology).
p38 MAP Kinase activity was analysed by a specific immunoprecipi-
tation with antiphospho-specific p38 MAP Kinase antibody
(Thr180 ⁄ Tyr182) followed by an in vitro kinase assay of its sub-
strate, ATF-2, according to the manufacturer’s instruction as
described previously (Singh et al., 2005). The samples were sepa-
rated by a 10% SDS–PAGE, transferred to membranes and blotted
with anti-phospho-specific ATF-2 antibody.
MAPKAP Kinase2 assay
The activity of MAPKAP Kinase2 was analysed using MAPKAP
kinase2 assay kit (MAPKAP Kinase2 Immunoprecipitation Kinase
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Assay Kit; non-radioactive; Upstate, Lake Placid, NY, USA) by a
specific immunoprecipitation with anti MAPKAP Kinase2 antibody
followed by an in vitro kinase assay of its substrate, Hsp27, accord-
ing to the manufacturer’s instruction. Briefly, 1 mg of cell lysates
was incubated with 10 ll of resuspended anti MAPKAP Kinase2-
agarose conjugate at 4C for 1.5 h to immunoprecipitate MAPKAP
Kinase2. The antibody ⁄ agarose ⁄ enzyme immunocomplex was
washed with 100 ll ice-cold lysis buffer and subsequently with
kinase buffer and then analysed for kinase activity. Immunoprecipi-
tated MAPKAP Kinase2 was then incubated with 10 ll (0.5 lg) of
recombinant Hsp27 in 50 ll of kinase buffer containing 100 lM
ATP for 45 min at 30C with vigorous shaking. The samples were
then subjected to SDS–PAGE followed by immunoblotting with the
phosphor-Hsp-27 antibody and a secondary antibody for enhanced
chemiluminiscence.
Reporter and expression vectors
The expression vectors pMI (2135 ⁄ +136), pMT2.2 (2236 ⁄ +59) and
pCMVbGal were gifted by Dr Robert Ballotti, Institut National de
la Sante¢ et de la Researche Me¢ dicale, France. The plasmid pMI
contains a 2.1-kb fragment of microphthalmia promoter upstream
of the luciferase coding sequence in pGL2 basic vector. The plas-
mid pMT2.2 contains a 2.2-kb fragment of mouse tyrosinase pro-
moter upstream of the luciferase coding sequence in pGL2 basic
vector. The expression vector pRSV-Flag-MKK3 (Ala) and pcDNA3-
Flag-MKK6 (K82A), encoding DN MKK3 and catalytically dead DN
MKK6 respectively, were generous gift from Dr Roger Davis, Uni-
versity of Massachusetts, Worcester, MA, USA. pRSV-Flag-MKK3
(Ala) and pCDNA3-Flag-MKK6 (K82A) were constructed by replac-
ing Ser-189 and Thr-193 with Ala and Lys-82 with Ala respectively
(Raingeaud et al., 1996). The empty vector pcDNA3.1 (Invitrogen
Life Technologies, Carlsbad, CA, USA) was used as a negative
control.
Transfection and Reporter Assays
B16F10 melanoma cells were seeded in 24-well plate and after
24 h the cells were transiently transfected with 0.25 lg of the test
plasmid (pMI, and pMT2.2) and 0.05 lg of pCMVbGal to control
the variability in transfection efficiency, using Lipofectamine 2000.
Twenty-four hours after transfection, cells were incubated with
PSL for indicated times. Then the cells were washed with PBS and
lysed using Reporter Lysis Buffer (Promega, Madison, WI, USA)
and assayed for luciferase and b-Galactosidase activities using
Luciferase Assay System and b-Galactosidase Enzyme Assay
System respectively (Promega).
In experiments with DN MKK3 and DN MKK6, B16F10 cells
were stably transfected with 3 lg of DN MKK3 and 3 lg of
pcDNA3.1 or 3 lg of DN MKK6 and 3 lg of pcDNA3.1 or 3 lg of
DN MKK3 and 3 lg of DN MKK6 or 6 lg of empty vector
pcDNA3.1, all in the presence of 0.5 lg of pcDNA3.1 ⁄ NT-GFP (Invi-
trogen Life Technologies) as a control to measure transfection effi-
ciency, using Lipofectamine 2000 (Invitrogen Life Technologies). At
24 h after transfection, the transfected cells were selected with
1600 lg ⁄ ml G418. Then 1 · 106 stably transfected cells were pla-
ted per well in six-well plates and treated with 10 lg ⁄ ml of PSL for
1 h. The cells were then lysed and western blot analysis or p38
MAPK activity was measured.
Preparation of PSL for topical application on
C57BL ⁄6J mice skin
PSL was dissolved in 60% alcohol that facilitates penetration
through skin. A working concentration of 10 lg ⁄ ml was prepared in
0.2 ml of total volume, which was applied per cm2 each time with
repeat of three times in a single application.
Topical application of the PSL on telogenic
C57BL ⁄6J mouse skin
Five mice were included in an experimental set. Body surface
area of about 4 cm2 on both sides was clipped to remove
gray body coat hair to have the telogenic pinkish skin exposed,
alcoholic extract was applied to the skin surface drop wise
(0.2 ml ⁄ cm2) with gentle rubbing (using the finger tips). On the
opposite side of the same mouse, equivalent amount of 60%
aqueous alcohol vehicle was applied identically. The process was
repeated three times in a single application and each time was
followed by irradiation with IR exposure (IR lamp, Infraphil,
230 V ⁄ 150 W; Philips, Mumbai, India) from a distance of approxi-
mately 45 cm for 5 min. The whole process was carried out twice
a day for a period of 45 days without any interruption in applica-
tion programme. Changes in skin colour and associated hair
growth were monitored on a regular basis.
Histological examination of C57BL ⁄6J mice skin
specimen
After local anaesthesia with lignocaine hydrochloride, skin speci-
mens were dissected out by incisional biopsy (4–6 mm and full
depth including subcutaneous tissue) from both the PSL and
vehicle-treated sites. Skin samples were fixed in 10% neutral-
buffered formalin and embedded in paraffin and then cut into 5 lm
thick sections in a microtome. These were then stained by
Masson–Fontana silver staining technique (Bancroft and Stevens,
1982) for melanin. Paraffin embedded tissue sections were also
used for immunohistochemistry studies.
Masson–Fontana silver staining for melanin
Formalin fixed, paraffinised sections were deparaffinised in xylene
and then hydrated. The sections were then treated with ammonia-
cal silver nitrate solution for 1 h at 63C and then toned with 0.1%
Gold Chloride for 10 min, washed with distilled water and subse-
quently treated with 5% sodium thiosulphate for 5 min and washed
with distilled water. The sections were counterstained with 1%
neutral red for 5 min. After washing in distilled water, the sections
were dehydrated in 95% alcohol, absolute alcohol and cleared in
xylene, and finally mounted in crystal mounting medium and
observed under optical microscope (Model: OLYMPUS 1 · 70).
Immunohistochemistry
The expression of Mitf was viewed in skin tissue sections by indi-
rect immunofluorescence using standard IHC techniques (Passer-
on et al., 2007). After deparaffinisation in xylene, skin samples
were processed with ethanol and then treated with methanol at
)20C for 10 min. Subsequently it was incubated with 10 mM
sodium citrate buffer (pH 6.0) at 95C for 5 min for antigen
retrieval and then immersed in blocking solution (10% goat serum
containing 2% BSA) for 1 h at room temperature. The skin speci-
mens were then incubated with primary antibody, rabbit antibody
(1:10, diluted in 2% BSA) overnight at 4C. This was washed in
PBS three times 10 min each followed by incubation with second
antibody, fluorescein isothiocyanate (FITC)-conjugated goat anti
rabbit IgG (1:100, diluted in blocking serum) for 1 h at 37C.
Finally, the sections were washed three times with PBS for
15 min at each time and mounted in crystal mounting medium
and observed under inverted fluorescence microscope (Model:
OLYMPUS 1 · 70).
Statistics
Differences between results were assessed for significance using
the Student’s t test.
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